Purpose: Reoperative durable left ventricular assist device (LVAD) insertion after coronary artery bypass grafting (CABG) is challenging due to potential injury to bypass grafts, great vessels, or the right ventricle (RV). We sought to compare the less invasive (LI) approach to the full sternotomy (FS) technique for LVAD implantation in patients with a prior history of CABG.
Methods: From March 2012 to April 2023, 29 patients with a history of CABG underwent reoperative LVAD implantation: Group FS, N = 16, and Group LI, N = 13. The LI approach includes an upper hemisternotomy and left thoracotomy without dissecting around the RV and bypass grafts.
Results: The median age was 68 years in Group FS and 70 years in Group LI (p = 0.83). HeartMate II was only used in group FS (FS: 56.3% [N = 9] vs. LI: 0%), whereas HeartWare (FS: 31.3% [N = 5] vs. LI: 53.8% [N = 7]) and Heartmate 3 (FS: 12.5% [N = 2] vs. LI: 46.2% [N = 6]) were used in both groups. None of the patients experienced intraoperative injury of bypass grafts. In isolated LVAD implantation, cardiopulmonary bypass time was comparable between groups (FS: 92 [68, 96] min vs. LI: 82 [61, 96] min, p = 0.33). The incidence of severe RV failure requiring mechanical support was lower in Group LI (FS: 43.8% [N = 7] vs. LI: 0%, p = 0.02). Hospital mortality was numerically lower in the LI group (FS: 31.3% [N = 5] vs. LI: 9.1% [N = 1], p = 0.35). One-year estimated survival rates were not significantly different (FS: 68.8% ± 11.6% vs. LI: 81.8% ± 11.6%, p = 0.85).
Conclusions: The less invasive technique for reoperative LVAD insertion after CABG may improve outcomes by reducing RV failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aor.14984 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Aortic Root and Valve Morphology With De Novo Aortic Valve Regurgitation After Implantation of Left Ventricular Assist Device.
Artif Organs
March 2025
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Background: The development of aortic valve regurgitation (AR) negatively affects the survival of patients with continuous-flow left ventricular assist device (LVAD) support. Although several risk factors have been identified, little is known about the effect of preoperative aortic root and valve morphology on the development of de novo AR after LVAD implantation.
Methods: Between April 2018 and September 2023, 87 patients underwent durable LVAD implantation at our department.
Why Is Social Reintegration Support for Patients With Left Ventricular Assist Device Necessary?
Circ Rep
March 2025
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University Kagawa Japan.
Left ventricular assist devices (LVADs) serve as critical life-sustaining therapy for patients with end-stage heart failure awaiting heart transplantation, significantly improving survival rates and enabling social reintegration. However, many patients with LVAD face multiple challenges in their daily lives and social reintegration, such as anxiety about the device, low societal awareness, and economic and psychological burdens. In Japan, where prolonged waiting periods for heart transplants are inevitable, these challenges further exacerbate the economic and psychological burdens on both patients and caregivers.
View Article and Find Full Text PDFSex-based Differences in the Utility and Outcomes of Left Ventricular Assist Devices.
J Saudi Heart Assoc
February 2025
Heart Centre, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
The totality of evidence suggests that there remains a significant disparity in the use of left ventricular assist devices (LVADs) and heart transplantation (HT) in women. This disparity persists even after accounting for differences in baseline characteristics, comorbidities, and cardiovascular risk factors between men and women undergoing LVAD implantation as a bridge to HT. Generally, women are less likely to undergo HT, leading to a higher mortality rate in women on the HT waiting list.
View Article and Find Full Text PDFEndostatin and Cystatin C as Predictors of 1 Month Renal Function Change in Patients With Left Ventricular Assist Device Support.
ASAIO J
March 2025
From the Division of Cardiothoracic Transplantation and Circulatory Support, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
First-month renal function trajectories after left ventricular assist device (LVAD) implantation vary widely. Lack of renal function improvement (RFI) and postoperative acute kidney injury (AKI) are associated with increased mortality. This study evaluates plasma levels of endostatin and cystatin C as predictors of RFI and AKI 1 month post-LVAD implantation.
View Article and Find Full Text PDFHome sleep apnea testing in patients with continuous flow LVAD: is it feasible?
J Clin Sleep Med
March 2025
University of Minnesota, Minneapolis, MN.
Study Objectives: The incidence of sleep-related breathing disorder (SRBD) remains unclear in patients with a continuous flow left ventricular assist device (LVAD). Polysomnography (PSG) remains the gold standard for diagnosis, but logistical challenges make home sleep apnea testing (HSAT) a more practical alternative. WatchPat has failed to accurately diagnose SRBD in this population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!